Results 31 to 40 of about 1,572 (142)

Successful outcome of second allogeneic bone marrow transplantation for blastic plasmacytoid dendritic cell neoplasm with MYC locus rearrangement

Leukemia Research Reports, 2019
A 62-year-old male was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) with a MYC rearrangement. Four months after the first unrelated bone marrow transplantation (BMT), he developed the relapsed BPDCN.
Takeharu Kato, Hidehiro Itonaga, Jun Taguchi, Junya Makiyama, Machiko Fujioka, Masataka Taguchi, Makiko Horai, Yasushi Sawayama, Daisuke Niino, Yoshitaka Imaizumi, Tomoko Hata, Shinichiro Yoshida, Kana Sakamoto, Kengo Takeuchi, Koichi Ohshima, Yasushi Miyazaki   +15 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications

Haematologica, 2010
Background Blastic plasmacytoid dendritic cell neoplasm is a rare malignancy that typically follows a highly aggressive clinical course in adults, whereas experience in children with this disease is very limited.Design and Methods This retrospective ...
Armin G. Jegalian, Nataliya P. Buxbaum, Fabio Facchetti, Mark Raffeld, Stefania Pittaluga, Alan S. Wayne, Elaine S. Jaffe   +6 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm

, 2017
Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignant neoplasm originating from precursor plasmacytoid dendritic cells. Blastic plasmacytoid dendritic cell neoplasm shows a characteristic immunophenotype in which the tumor cells express CD4, CD56, TCL1, and bright CD123, and lack expression of lineage-specific myeloid and lymphoid ...
Yuranga Weerakkody, Tom Foster, Daniel Bell   +2 more
  +6 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm Mimicking Erythema Nodosum: A Case Report

Annals of Internal Medicine: Clinical Cases, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as blastic natural killer cell lymphoma, is a rare, difficult-to-diagnose, and aggressive hematologic malignancy.
Marino Hirata, Nozomu Yoshino, Maya Takazawa, Hisashi Oshiro, Shinichi Kako, Hitoshi Sugawara   +5 more
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm; A Report of Three Cases [PDF]

Iranian Journal of Medical Sciences, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic myeloid malignancy that is known to be derived from plasmacytoid dendritic cells which are characterized by expression of CD4, CD56, and more specific markers such as CD123. Here,
Akbar Safaei, Ahmad Monabati, Maral Mokhtari, Freidoon Solhjoo, Mehdi Montazer   +4 more
doaj   +1 more source

Regimen of Azacitidine Combined with GemOx in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report

Xiehe Yixue Zazhi, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly malignant hematological tumor derived from the precursor cells of plasmacytoid dendritic cells.
CHEN Xiaojun, LIU Yanquan, HU Xiaomei, HUANG Surong, SHEN Jianzhen   +4 more
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rapidly Progressive and Fatal Disease without Aggressive Intervention

Clinical Medicine Insights: Case Reports, 2013
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive myeloid neoplasm derived from plasmacytoid monocytes. The most common presentation involves cutaneous manifestations, which are often accompanied by bone marrow involvement.
Lindsey Prochaska, Christopher Dakhil, Sharad Mathur   +2 more
doaj   +1 more source

Indispensable role of immunophenotyping in diagnosing leukemic phase of blastic plasmacytoid dendritic cell neoplasm without cutaneous manifestation

Leukemia Research Reports, 2022
Blastic plasmacytoid dendritic cell neoplasm usually presents as skin lesions. Diagnostic error occurs when it primarily presents in leukemic phase without skin involvement.
Hareem Alam, Nabiha Saeed, Anila Rashid
doaj   +1 more source

Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment

British Journal of Haematology, EarlyView.
Summary Chemotherapy‐induced neutropenia, monitored by peripheral blood absolute neutrophil count (ANC), increases the risk of bloodstream infections (BSIs). However, ANC may not reflect the total neutrophil population, as it omits neutrophils at extravascular sites.
Johanna Vævest Nymann Eriksen, Silvia de Pietri, Mathias Rathe, Henrik Hasle, Christian Enevold, Claus H. Nielsen, Kjeld Schmigelow, Claus Moser, Klaus Müller, Sarah Weischendorff   +9 more
wiley   +1 more source

Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Neutrophil‐extracellular traps are net‐like material released by triggered neutrophils and composed of decondensed chromatin linked to nuclear proteins. Elastase, one of the fourth most represented neutrophil‐specific serine proteases stored in azurophil granules of naïve neutrophils, exerts various actions, including degradation ...
Pasqualina Scala, Anna Maria Della Corte, Angela Bertolini, Marisa Gorrese, Francesca Picone, Bianca Serio, Danilo De Novellis, Laura Mettivier, Luca Pezzullo, Maria Carmen Martorelli, Denise Morini, Matteo D'Addona, Bianca Cuffa, Carmine Selleri, Valentina Giudice   +14 more
wiley   +1 more source